Sociedad Americana de Hirudoterapia

Antithrombotic and Antiplatelet Drug Toxicity

Review published in Critical care clinics (2021)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosLiss DB et al. · Critical care clinics, 2021

Abstract

Anticoagulant and antiplatelet drugs target a specific portion of the coagulation cascade or the platelet activation and aggregation pathway. The primary toxicity associated with these agents is hemorrhage. Understanding the pharmacology of these drugs allows the treating clinician to choose the correct antidotal therapy. Reversal agents exist for some of these drugs; however, not all have proven patient-centered outcomes. The anticoagulants covered in this review are vitamin K antagonists, heparins, fondaparinux, hirudin derivatives, argatroban, oral factor Xa antagonists, and dabigatran. The antiplatelet agents reviewed are aspirin, adenosine diphosphate antagonists, dipyridamole, and glycoprotein IIb/IIIa antagonists. Additional notable toxicities are also reviewed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood CoagulationFibrinolytic AgentsHemorrhageHumansPlatelet Aggregation Inhibitors

Resumen

Anticoagulant and antiplatelet drugs target a specific portion of the coagulation cascade or the platelet activation and aggregation pathway.

Por qué esto importa para la hirudoterapia

This review covers the pharmacology and toxicity—primarily hemorrhage—of anticoagulant and antiplatelet drugs, listing hirudin derivatives among the anticoagulants discussed alongside vitamin K antagonists, heparins, fondaparinux, argatroban, oral factor Xa antagonists, and dabigatran. It also addresses reversal agents and notes that not all have proven patient-centered outcomes. The inclusion of hirudin derivatives places this within ASH's domain of hirudin-related compounds. However, the abstract provides no specific data, findings, or conclusions about hirudin derivatives; they appear only as one drug class in a broad toxicology overview, with no original research, no hirudotherapy content, and no mention of leeches.

Citación

Antithrombotic and Antiplatelet Drug Toxicity

Liss DB et al. · Critical care clinics, 2021

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Clinical EvidenceClinical ApplicationsHirudinDirect Thrombin InhibitorsAnticoagulation CompoundsHemostasisOtolaryngologyPost-Thrombotic Syndrome

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.